Flavonoid. Racemic mixture. Urinary metabolite of daidzein. Inhibits 12-O-tetradecanoylphorbol 13-acetate (TPA)-induced neoplastic cell transformation by targeting the MEK/ERK/p90RSK/activator protein-1 signalling pathway. Shows positive effects on the incidence of prostate cancer and physiological changes after menopause. Functions as a DHT blocker. Preferentially activates estrogen receptor β (ERβ).
Product Details
| Alternative Name: | (±)-Equol, 3,4-Dihydro-3-(4-hydroxyphenyl)-2H-1-benzopyran-7-ol, 4’,7-Dihydroxyisoflavane |
| |
| Formula: | C15H14O3 |
| |
| MW: | 242.3 |
| |
| CAS: | 531-95-3, 94105-90-5 |
| |
| MI: | 14: 3644 |
| |
| Purity: | ≥98% (HPLC, TLC) |
| |
| Appearance: | White to light yellow crystalline solid. |
| |
| Solubility: | Soluble in DMSO, methanol or 100% ethanol; insoluble in water. |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | -20°C |
| |
| Handling: | Protect from light. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Equol, a metabolite of the soybean isoflavone daidzein, inhibits neoplastic cell transformation by targeting the MEK/ERK/p90RSK/activator protein-1 pathway: N.J. Kang, et al.; J. Biol. Chem.
282, 32856 (2007),
Abstract;
Full Text
Isoflavones, equol and cardiovascular disease: pharmacological and therapeutic insights: K.A. Jackman, et al.; Curr. Med. Chem.
14, 2824 (2007),
Abstract;
High concordance of daidzein-metabolizing phenotypes in individuals measured 1 to 3 years apart: C.L. Frankenfeld, et al.; Br. J. Nutr.
94, 873 (2005),
Abstract;
Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents: H. Akaza, et al.; Jpn. J. Clin. Oncol.
34, 86 (2004),
Abstract;
Full Text
Equol is a novel anti-androgen that inhibits prostate growth and hormone feedback: T.D. Lund, et al.; Biol. Reprod.
70, 1188 (2004),
Abstract;
Full Text
Mammographic density in relation to daidzein-metabolizing phenotypes in overweight, postmenopausal women: C.L. Frankenfeld, et al.; Cancer Epidemiol. Biomarkers Prev.
13, 1156 (2004),
Abstract;
Full Text
Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells: S.O. Mueller, et al.; Toxicol. Sci.
80, 14 (2004),
Abstract;
Full Text
